Specialties – Page 218

Relacorilant Plus Nab-Paclitaxel: A New Standard for Platinum-Resistant Ovarian Cancer?

By MedXY 08/03/2025

Relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival in platinum-resistant ovarian cancer, with a favorable safety profile, suggesting a potential new treatment standard.

Clinical Updates news Orthopedics Specialties

Surgery Versus Corticosteroid Injection for Carpal Tunnel Syndrome: Insights from the DISTRICTS Randomised Controlled Trial

By MedXY 08/03/2025

The DISTRICTS trial demonstrates that initial surgical treatment for carpal tunnel syndrome leads to significantly higher recovery rates at 18 months compared to starting with corticosteroid injections, despite similar adverse event profiles.

Clinical Updates news Oncology Specialties

Retifanlimab Plus Carboplatin-Paclitaxel: A New Standard for Advanced Squamous Cell Anal Cancer?

By MedXY 08/03/2025

Retifanlimab combined with carboplatin-paclitaxel significantly prolongs progression-free survival in advanced squamous cell anal cancer, offering a promising new first-line standard of care.

Clinical Updates news Oncology Specialties

First-Line Maintenance Therapy with Lurbinectedin Plus Atezolizumab in ES-SCLC: Clinical Impact of the IMforte Phase 3 Trial

By MedXY 08/03/2025

The IMforte phase 3 trial demonstrates that lurbinectedin plus atezolizumab as first-line maintenance significantly prolongs progression-free and overall survival in extensive-stage small-cell lung cancer, albeit with increased hematologic toxicity.

AI Clinical Updates General Surgery news Specialties

Online Video Versus Face-to-Face Preoperative Consultation for Major Abdominal Surgery: Insights from the VIDEOGO Non-Inferiority Trial

By MedXY 08/03/2025

The VIDEOGO trial shows that online video consultations are non-inferior to face-to-face consultations for preoperative assessment in major abdominal surgery, achieving similar patient satisfaction and information recall.

Clinical Updates news Public Health Respiratory Specialties

Targeted Pneumococcal Vaccination in New Older Adult Care Home Residents: Evidence from National Surveillance in England

By MedXY 08/03/2025

Vaccinating new older adult care home residents with PCV20 or PPV23 could prevent substantially more invasive pneumococcal disease cases and deaths per dose than standard age-based vaccination, supporting policy revision.

Clinical Updates Infectious Diseases Public Health Specialties

Real-World Safety and Effectiveness of MVA-BN Vaccination Against Mpox: Evidence from German, Systematic Review, and Immunogenicity Cohorts

By MedXY 08/03/2025

MVA-BN vaccination is safe and effective against mpox in at-risk populations, but reduced protection is noted in people living with HIV. Dose strategies and patient immunological status may affect outcomes.

Allergy & Immunology Clinical Updates news Rheumatology Specialties

Long-term Impact of Anifrolumab on Quality of Life in Systemic Lupus Erythematosus: Insights from the TULIP-LTE Trial

By MedXY 08/03/2025

A 4-year phase 3 extension study shows that anifrolumab improves patient-reported outcomes and quality of life in systemic lupus erythematosus, with a favorable safety profile.

$Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial$

Clinical Updates news Oncology Radiology Specialties Urology

Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial

By MedXY 08/03/2025

The PACE-C phase 3 trial shows that stereotactic body radiotherapy (SBRT) and moderately hypofractionated radiotherapy (MHRT) have comparable early toxicity profiles in intermediate- and high-risk prostate cancer patients.

Clinical Updates news Oncology Specialties

Ten-Year Outcomes of Partial-Breast Radiotherapy After Breast Conservation Surgery: Insights from the UK IMPORT LOW Trial

By MedXY 08/03/2025

The IMPORT LOW trial confirms that partial-breast and reduced-dose radiotherapy are as effective and safe as whole-breast radiotherapy for selected women with early breast cancer, supporting their use as standard care.

Clinical Updates news Psychiatry Specialties

Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia

By MedXY 08/03/2025

Weekly LYN-005 demonstrated pharmacokinetic equivalence to daily risperidone, sustained therapeutic levels, and manageable safety in clinically stable patients, offering a novel option to address non-adherence in schizophrenia.

Clinical Updates Diabetes & Endocrinology news Psychiatry Specialties

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia

By MedXY 08/03/2025

Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.

Clinical Updates HIV/AIDS news Specialties

Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial

By MedXY 08/03/2025

The PASO-DOBLE trial demonstrated non-inferiority of dolutegravir/lamivudine versus bictegravir/FTC/TAF for maintenance in virologically suppressed HIV-1 adults, with similar efficacy and safety over 48 weeks.

Clinical Updates news Oncology Specialties

Zanidatamab Plus Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastro-Oesophageal Adenocarcinoma: Clinical Efficacy and Safety Insights from a Phase 2 Study

By MedXY 08/03/2025

Zanidatamab combined with chemotherapy shows promising efficacy and manageable safety in first-line treatment of HER2-positive advanced gastro-oesophageal adenocarcinoma, with durable responses and improved survival outcomes.

$Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results$

Clinical Updates Hematology-Oncology news Specialties

Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results

By MedXY 08/02/2025

The combination of bexmarilimab and azacitidine shows manageable safety and promising efficacy in high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukaemia, supporting further investigation.

Clinical Updates Diabetes & Endocrinology news Specialties

Continuous Glucose Monitoring in Gestational Diabetes: Insights from the DipGluMo Randomized Controlled Trial in Switzerland

By MedXY 08/02/2025

The DipGluMo trial found that real-time continuous glucose monitoring does not improve perinatal outcomes versus self-monitoring in gestational diabetes, but is preferred by patients for ease of use.

Clinical Updates Hematology-Oncology news Specialties

Avatrombopag in Pediatric Immune Thrombocytopenia: Evidence from the AVA-PED-301 Phase 3b Trial

By MedXY 08/02/2025

The AVA-PED-301 phase 3b trial demonstrates avatrombopag’s efficacy and safety as an oral thrombopoietin receptor agonist for children and adolescents with persistent or chronic immune thrombocytopenia.

Clinical Updates news Oncology Specialties

Toripalimab Plus Bevacizumab vs Sorafenib as First-Line Therapy in Advanced Hepatocellular Carcinoma: Results from the Phase 3 HEPATORCH Trial

By MedXY 08/02/2025

The HEPATORCH phase 3 trial demonstrates that toripalimab plus bevacizumab significantly improves survival outcomes versus sorafenib in previously untreated advanced hepatocellular carcinoma, with manageable safety.

Clinical Updates Hematology-Oncology news Specialties

Mitapivat Offers New Hope for Adults with Non-Transfusion-Dependent α- and β-Thalassaemia: Results from the Phase 3 ENERGIZE Trial

By MedXY 08/02/2025

Mitapivat significantly improves haemoglobin levels in adults with non-transfusion-dependent α- or β-thalassaemia, offering a promising oral therapeutic option with manageable safety profile.

Clinical Updates Diabetes & Endocrinology news Oncology Specialties

Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer: Insights from the IoN Trial

By MedXY 08/02/2025

The IoN trial demonstrates that postoperative radioiodine ablation can be safely omitted in most patients with low-risk differentiated thyroid cancer after total thyroidectomy, without compromising recurrence-free survival.